Sivia Capital Partners LLC Acquires 158 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sivia Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 21.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 891 shares of the medical research company’s stock after buying an additional 158 shares during the quarter. Sivia Capital Partners LLC’s holdings in Thermo Fisher Scientific were worth $443,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at $25,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $28,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. Ameriflex Group Inc. purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $30,000. Finally, Noble Wealth Management PBC purchased a new position in Thermo Fisher Scientific during the 4th quarter worth $35,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 0.9%

Shares of TMO opened at $401.99 on Friday. The business’s 50-day moving average price is $420.74 and its 200-day moving average price is $495.81. Thermo Fisher Scientific Inc. has a twelve month low of $390.50 and a twelve month high of $627.88. The stock has a market cap of $151.75 billion, a PE ratio of 24.32, a P/E/G ratio of 2.99 and a beta of 0.78. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the prior year, the business posted $5.11 earnings per share. The company’s revenue was up .2% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 23rd. Finally, UBS Group lowered their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $605.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.